Midatech Pharma Plc (MTPH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The companys products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimmune diseases, pipeline, Q-octreotide, opsisporin, HCC, glioblastoma and diabetes vaccine. Midatechs products are used in treatment of diabetes; rare cancers including brain, ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions. It collaborates with universities, and specialty and major pharmaceutical companies to develop its platform technologies. The company operates through its manufacturing facility in Bilbao, and research facility in Cardiff. Midatech is headquartered in Abingdon, the UK.

Midatech Pharma Plc (MTPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14
Venture Financing 15
Q Chip Raises US$3 Million Venture Financing 15
Partnerships 16
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 16
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 17
Midatech Pharma Enters into Agreement with Ophthotech 18
Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 19
DARA BioSciences Enters into Commercialization Agreement with Onxeo 20
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 21
Midatech Enters into Research Collaboration Agreement with Middlesex University 22
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 23
Midatech Enters into Research and Collaboration Agreement with The Open University 24
Midatech Enters Into Joint Venture With MonoSol Rx 25
Licensing Agreements 26
Midatech Pharma Enters Into Licensing Agreement with Novartis 26
Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 27
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 28
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 29
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 30
Equity Offering 31
Midatech Pharma Raises USD8 Million in Private Placement of Shares 31
Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 32
Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 33
Midatech Pharma Raises USD50 Million in IPO 34
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 36
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 37
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 38
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 39
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 40
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 41
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 42
DARA BioSciences Completes Public Offering Of Units For US$10 Million 43
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 45
Acquisition 47
Midatech Pharma Acquires Dara BioSciences 47
Midatech Pharma Acquires Q Chip 49
DARA BioSciences Acquires Oncogenerix 50
Midatech Pharma Plc - Key Competitors 51
Midatech Pharma Plc - Key Employees 52
Midatech Pharma Plc - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Joint Venture 53
Recent Developments 54
Strategy And Business Planning 54
Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility 54
Financial Announcements 55
Apr 23, 2018: Midatech Pharma: Audited financial results for the year ended 31 December 2017 55
Sep 28, 2017: Midatech Pharma: Interim results for the six months ended 30 June 2017 61
Apr 04, 2017: Midatech Pharma Announces Audited financial results for the year ended 31 December 2016 65
Jan 20, 2017: Midatech Pharma Provides Trading Update 66
Corporate Communications 67
Jun 01, 2018: Midatech Pharma: Board change 67
Mar 15, 2018: Midatech announces changes in Senior Management Team 68
Government and Public Interest 69
Nov 23, 2017: Midatech secures manufacturing certification from Spanish regulatory authority 69
Product News 70
May 22, 2017: Midatech announces progress update on brain cancer therapies 70
01/16/2018: Midatech and UCSF receive IND approval for DIPG treatment MTX110 71
Clinical Trials 72
May 25, 2018: Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer 72
Jul 26, 2017: Midatech Pharma: Completion of pre-clinical liver cancer programme 73
Other Significant Developments 74
Jul 25, 2018: Midatech Pharma: Trading update 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List Of Tables


Midatech Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14
Q Chip Raises US$3 Million Venture Financing 15
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 16
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 17
Midatech Pharma Enters into Agreement with Ophthotech 18
Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 19
DARA BioSciences Enters into Commercialization Agreement with Onxeo 20
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 21
Midatech Enters into Research Collaboration Agreement with Middlesex University 22
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 23
Midatech Enters into Research and Collaboration Agreement with The Open University 24
Midatech Enters Into Joint Venture With MonoSol Rx 25
Midatech Pharma Enters Into Licensing Agreement with Novartis 26
Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 27
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 28
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 29
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 30
Midatech Pharma Raises USD8 Million in Private Placement of Shares 31
Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 32
Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 33
Midatech Pharma Raises USD50 Million in IPO 34
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 36
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 37
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 38
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 39
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 40
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 41
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 42
DARA BioSciences Completes Public Offering Of Units For US$10 Million 43
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 45
Midatech Pharma Acquires Dara BioSciences 47
Midatech Pharma Acquires Q Chip 49
DARA BioSciences Acquires Oncogenerix 50
Midatech Pharma Plc, Key Competitors 51
Midatech Pharma Plc, Key Employees 52
Midatech Pharma Plc, Subsidiaries 53
Midatech Pharma Plc, Joint Venture 53

List Of Figures


Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11

Midatech Pharma Plc (MTPH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The companys products include gelclair, oravig, soltamox and zuplenz. It conducts

USD 250 View Report

Midatech Pharma US Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Midatech Pharma US Inc Company Profile is a detailed strategic and analytical report on Midatech Pharma US Inc. The 2018 version of the report offers detailed insights into the companys

USD 200 View Report

Destiny Pharma Plc (DEST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Destiny Pharma Plc (Destiny Pharma), formerly Destiny Pharma Ltd, a subsidiary of Destiny Pharma Holdings Ltd is a drug development and discovery company that offers commercial exploitation and clinical development

USD 250 View Report

Immupharma Plc (IMM) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain,

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available